4th Quarter - Report

AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS for AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS

Firm
Client
Income
—
Expenses
$250,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Labor-Health and Human Services appropriations, fiscal year 2011; support for Administration's request for FDA funding. Contacts concerning funding for section 3503 of Affordable Care Act (P.L. 111-148).

LobbyistCovered position, as disclosed
JOSEPH M HILL —
BRIAN M MEYER —
KAREN NOONAN —
CHRISTOPHER J TOPOLESKI —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

Communication with Centers for Medicare and Medicaid Services regarding influenza vaccines, conditions of participation, Innovation Center, funding for specialized pharmacy resident programs, Part D utilization review and direct reimbursement under the Medicare program.

LobbyistCovered position, as disclosed
JOSEPH M HILL —
BRIAN M MEYER —
KAREN NOONAN —
CHRISTOPHER J TOPOLESKI —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Centers For Disease Control & Prevention (CDC)

Pharmacy PHA

H.R. 2245, S. 296, "Preserving Access to Life-Saving Medications Act," all provisions. Contact concerning Food and Drug Administration (FDA) authority to manage drug shortages. Communications to FDA on dietary supplements, long-acting opiods, Prescription Drug User Fee Act presentation at FDA public meeting. Communications with the National Institute for Occupational Safety and Health (NIOSH) on their proposed list of hazardous drugs for 2012. Support for S. 1584, "The Drug Safety and Accountability Act," a bill to ensure drug supply safety and give FDA mandatory recall authority.

LobbyistCovered position, as disclosed
JOSEPH M HILL —
BRIAN M MEYER —
KAREN NOONAN —
CHRISTOPHER J TOPOLESKI —

Contacted: Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); SENATE

Bills named: S. 1584 (112th), S. 296 (112th), H.R. 2245 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.